"Cytochrome P-450 CYP2B6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme subtype that oxidizes a diverse array of XENOBIOTICS. The expression of CYP2B6 varies widely between individuals which is due to the high rate of GENETIC POLYMORPHISMS. Examples of drugs metabolized by CYP2B6 include BUPROPION; efavirenz; CYCLOPHOSPHAMIDE; and MEPERIDINE.
| Descriptor ID |
D065702
|
| MeSH Number(s) |
D08.244.453.005.575 D08.244.453.491.344 D08.811.682.690.708.170.010.575 D08.811.682.690.708.170.450.344 D12.776.422.220.453.010.575 D12.776.422.220.453.491.344
|
| Concept/Terms |
Cytochrome P-450 CYP2B6- Cytochrome P-450 CYP2B6
- CYP2B6, Cytochrome P-450
- Cytochrome P 450 CYP2B6
- P-450 CYP2B6, Cytochrome
- CYPIIB6
- 1,4-Cineole 2-exo-Monooxygenase
- 1,4 Cineole 2 exo Monooxygenase
- 2-exo-Monooxygenase, 1,4-Cineole
- Cytochrome P450 2B6
- P450 2B6, Cytochrome
- CYP2B6
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2B6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2B6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2B6" by people in this website by year, and whether "Cytochrome P-450 CYP2B6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2B6" by people in Profiles.
-
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations. Clin Pharmacol Ther. 2024 03; 115(3):576-594.
-
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2021 12 06; 73(11):e3902-e3909.
-
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clin Pharmacol Ther. 2021 04; 109(4):1034-1044.
-
Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. BMC Infect Dis. 2016 Feb 02; 16:56.
-
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15; 60(12):1860-3.
-
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. J Infect Dis. 2013 Aug 15; 208(4):662-71.
-
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e55-7.
-
Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Eur J Clin Pharmacol. 2012 Apr; 68(4):339-47.
-
Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J. 2011 Nov; 30(11):1001-3.
-
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006 Sep 15; 43(6):783-6.